Besivo's reimbursement standards expanded

The MOHW, finalizes a partial revision of the Criteria, effective on February 1

If the patient progresses to liver cancer during treatment with Besifovir oral medications, the benefit is still acceptable.

 

In the case of Ramosetron HCl oral medications, there will be no restriction on the duration of administration, up to 12 weeks.

 

The Ministry of Health and Welfare was confirmed on 28th after hearing opinions by the 22nd on the partial amendment of 'Details on the Standards and Methods of Application of Medical Benefits (Pharmaceuticals)'.

 

The effective date is the 1st of next month.

 

Looking at the reimubrsement criteria to be applied next month, patients with chronic hepatitis B begin treatment with Besifovir (generic for Besivo), and if the disease progresses to liver cancer, the patient can continue to receive the benefits.

 

This means that even if hepatitis B patients are diagnosed with cancer from now on, they will receive the benefit for continuous administration.

 

There is no restriction on the duration of the administration of Ramosetron HCl oral medications such as Irribow by Korea Astellas.

 

Currently, the duration of administration is limited to a maximum of 12 weeks, and further administration is being reduced.

 

As Boryeong’s combination drug of Fimasartan, Amlodipine & Rosuvastatin is newly listed on the 1st day, it is added to the 'high blood pressure + hyperlipidemia' complex oral reimbursement standard.

 

When using Infliximab products such as Crohn's disease treatment, Remicade by Janssen, immunoglobulin-resistant refractory Kawasaki disease (including typical and atypical) that exceeds the licensed range is also approved.

 

Basiliximab injections, such as Simulect by Novartis , used in adult kidney transplantation, specify the dosage and frequency of heart, liver, lung, small intestine transplantation, and pancreatic and pancreatic transplants in excess of the approved range.

 

This makes the standard clearer than before.

 

In detail, according to the permission (use and dose), it is specified as 20 mg per dose and 2 doses.

 

In case of Abatarcept injections, such as 250mg of Orencia inj and Orencia subQ pfs(125mg) by BMS Korea, benefits are expanded by adding 'expandable minority arthritis' among pediatric idiopathic arthritis.

 

Agalsidase β 35mg injections, such as Fabrazyme from Sanofi-aventis Korea, an enzyme replacement therapy for Fabry disease's confirmed patients, are changed based on the amounts listed on the current insurance benefit list.

 

The ingredient is actualized.

 

In addition, Jext inj (children/adults, Epinephrine single use autoinjector) and Dibenyline capsules (Phenoxybenzamine oral drugs), which were reimbursed as urgent drug and decided to be deleted due to supply failure, as of the 31st of the six-month grace period, the benefit will be also deleted.